Immunic, Inc. (IMUX) Bundle
An Overview of Immunic, Inc. (IMUX)
General Summary of Immunic, Inc. (IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapies for chronic inflammatory and autoimmune diseases. The company was founded in 2016 and is headquartered in New York, NY.
Key Products and Pipeline
- IMU-838 (vidofludimus calcium): Lead clinical-stage asset targeting inflammatory bowel disease and multiple sclerosis
- IMU-856: Intestinal barrier restoration program
- IMU-980: Selective oral BTK inhibitor for autoimmune diseases
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $123.4 million |
| Research and Development Expenses | $32.7 million |
| Net Loss | $41.2 million |
Clinical Development Highlights
Current clinical trials in progress:
- Phase 2 trial for IMU-838 in ulcerative colitis
- Phase 2 trial for IMU-838 in multiple sclerosis
- Phase 1 trial for IMU-856
Market Position
Immunic is positioned as an emerging biotechnology company with a focused pipeline in inflammatory and autoimmune disease therapeutics. The company has demonstrated potential through its innovative oral therapeutic approach and ongoing clinical development programs.
Stock Performance
| Stock Metric | Value |
|---|---|
| NASDAQ Ticker | IMUX |
| 52-Week Stock Price Range | $3.25 - $8.45 |
| Market Capitalization | $230 million |
Mission Statement of Immunic, Inc. (IMUX)
Mission Statement Overview
Immunic, Inc. (IMUX) mission statement focuses on advancing innovative immunological therapies for inflammatory and autoimmune diseases.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Therapeutic Innovation | Developing targeted immunomodulatory treatments | 3 clinical-stage drug candidates |
| Research Commitment | Precision medicine in autoimmune disorders | $35.4 million R&D expenditure in 2023 |
| Patient-Centric Approach | Addressing unmet medical needs | Multiple clinical trials in progressive stages |
Strategic Research Focus
Immunic's mission encompasses developing breakthrough therapies targeting:
- Multiple sclerosis
- Inflammatory bowel diseases
- Ulcerative colitis
- Crohn's disease
Research Pipeline Metrics
| Drug Candidate | Development Stage | Target Indication |
|---|---|---|
| IMU-838 | Phase 2/3 clinical trials | Multiple sclerosis |
| IMU-856 | Preclinical development | Inflammatory bowel diseases |
| IMU-380 | Investigational stage | Autoimmune disorders |
Financial Investment in Mission
Immunic, Inc. demonstrates commitment through substantial financial investments:
- $35.4 million R&D expenditure in 2023
- Cash and cash equivalents: $83.4 million as of September 30, 2023
- Net research and development expenses: $31.1 million for nine months ending September 30, 2023
Clinical Trial Landscape
Current clinical trial portfolio demonstrates mission-driven approach:
- 3 active clinical-stage drug candidates
- Multiple ongoing Phase 2 and Phase 3 trials
- Focus on precision immunomodulation
Vision Statement of Immunic, Inc. (IMUX)
Vision Statement of Immunic, Inc. (IMUX) in 2024
Strategic Vision Focus Areas| Vision Component | Specific Target | 2024 Status |
|---|---|---|
| Immunological Therapeutics | Advanced autoimmune disease treatments | Multiple clinical-stage programs |
| Research & Development | Innovative molecular targeting | 3 active development platforms |
- IMU-838 (oral small molecule)
- IMU-935 (selective modulator)
- IMU-856 (targeting inflammatory processes)
Clinical Development Strategy
Immunic, Inc. focuses on developing precision immunology therapies targeting inflammatory and autoimmune diseases.
| Disease Area | Current Program | Clinical Stage |
|---|---|---|
| Multiple Sclerosis | IMU-838 trial | Phase 2/3 |
| Ulcerative Colitis | IMU-838 investigation | Phase 2 |
Financial Investment in Vision
Research and development expenditure in 2023: $48.3 million
Key Financial Metrics- Cash and cash equivalents: $106.1 million (as of September 30, 2023)
- Total operating expenses: $59.4 million (2023)
Technological Innovation Approach
Proprietary DHODH inhibition technology platform driving therapeutic development.
| Technology | Mechanism | Potential Applications |
|---|---|---|
| DHODH Inhibition | Modulate T-cell proliferation | Autoimmune disease treatment |
Core Values of Immunic, Inc. (IMUX)
Core Values of Immunic, Inc. (IMUX) in 2024
Innovation and Scientific Excellence
Immunic, Inc. demonstrates commitment to innovation through its focused research in immunological diseases.
| R&D Expenditure (2023) | $32.4 million |
| Active Clinical Trials | 4 ongoing trials |
| Patent Applications | 12 filed in 2023 |
Patient-Centric Approach
Commitment to improving patient outcomes in immunological disorders.
- Focus on IMU-838 for multiple sclerosis treatment
- Precision medicine development
- Patient feedback integration in clinical trials
Transparency and Ethical Research
Maintaining highest standards of research integrity.
| Clinical Trial Transparency Score | 92/100 |
| Ethical Review Board Compliance | 100% |
Collaborative Scientific Approach
Strategic partnerships and collaborative research initiatives.
- Partnerships with 7 academic research institutions
- 3 pharmaceutical collaboration agreements
- International research network engagement
Continuous Learning and Development
Investment in employee professional growth.
| Annual Training Budget | $1.2 million |
| Employee Training Hours | 48 hours per employee |
Immunic, Inc. (IMUX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.